SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Apr 10, 2018

KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: April 10, 2018 · CIK: 0001372514 · Accession: 0001144204-18-019953

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-223887

Date

April 12, 2018

Author

Edward D. Silvera

Form

CORRESP

Company

KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)

Letter

Re: EyeGate Pharmaceuticals, Inc.

April 10,

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

Registration Statement on Form S-1 (File No. 333-223887)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by EyeGate Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. (Eastern Time), or as soon as practicable thereafter, on April 12, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

H.C. WAINWRIGHT & CO., LLC

By: /s/ Edward D. Silvera

Name: Edward D. Silvera

Title: Chief Operating Officer

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

Show Raw Text

CORRESP
1
filename1.htm

    April 10,
2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

 Re: EyeGate Pharmaceuticals, Inc.

Registration Statement on Form S-1 (File
No. 333-223887)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright &
Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by EyeGate
Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. (Eastern
Time), or as soon as practicable thereafter, on April 12, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms
that it is aware of its obligations under the Securities Act in connection with this offering.

H.C.
WAINWRIGHT & CO., LLC

 By: /s/ Edward D. Silvera

Name:
   Edward D. Silvera

Title:
     Chief Operating Officer

430 Park Avenue | New York, New York 10022
| 212.356.0500

Security services provided by H.C. Wainwright
& Co., LLC | Member: FINRA/SIPC

SecProbe.io